Lean Diabetes Study
NCT05407831 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2024-07-25
Summary
Systematic assessment of perinatal, behavioral and genetic risk factors will be evaluated in an underserved population with lean diabetes (LDM) as compared to a control population with obese type 2 diabetes (ODM).
Conditions
- Lean Diabetes Mellitus
Interventions
- GENETIC
-
Genetic
Calculate MODY probability
- BEHAVIORAL
-
Social habits
Alcohol vs Smoking vs Drug use
- OTHER
-
Perinatal stress
Survey
Sponsors & Collaborators
-
Leon Fogelfeld MD
lead OTHER_GOV
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-15
- Primary Completion
- 2023-07-26
- Completion
- 2023-07-26
Countries
- United States
Study Locations
More Related Trials
-
Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients
NCT00596973 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
NCT02721888 ·Status: TERMINATED ·Phase: PHASE4
-
Insulin Resistance and Insulin Secretion
NCT00073294 ·Status: WITHDRAWN ·Phase: NA
-
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
NCT04324229 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
NCT01771250 ·Status: COMPLETED ·Phase: PHASE1
-
Study TO Prevent Diabetes With Short-term Insulin Glargine Only
NCT01276912 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399 ·Status: COMPLETED ·Phase: PHASE4
-
Recombinant Human Leptin Therapy Effects on Insulin Action
NCT01207934 ·Status: COMPLETED ·Phase: NA
-
Regulation of Insulin Secretion by the GLP-1 Receptor
NCT02844907 ·Status: TERMINATED ·Phase: PHASE4
-
Novel Type 2 Diabetes Mellitus Preventive Therapies
NCT02351323 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
NCT03582956 ·Status: TERMINATED ·Phase: NA
-
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
NCT02109029 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
NCT05470504 ·Status: RECRUITING ·Phase: PHASE2
-
Liraglutide in Type 1 Diabetes
NCT01722240 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of GLP-1 Agonists on Gastric Volume
NCT05854979 ·Status: COMPLETED
-
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
NCT05569772 ·Status: RECRUITING ·Phase: PHASE3
-
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
NCT02969798 ·Status: RECRUITING ·Phase: NA
-
Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes
NCT03195400 ·Status: COMPLETED
-
Duodenal Exclusion for the Treatment of Type 2 Diabetes
NCT00534547 ·Status: WITHDRAWN ·Phase: NA
-
Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet
NCT05536232 ·Status: UNKNOWN ·Phase: NA
-
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
NCT01722266 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
NCT07313813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT05067621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Incretin Action in Physiology and Diabetes
NCT02550548 ·Status: COMPLETED ·Phase: PHASE1
-
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
NCT07252765 ·Status: RECRUITING